FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310644346> ?p ?o ?g. }

• W4310644346 endingPage "470" @default.
• W4310644346 startingPage "463" @default.
• W4310644346 abstract "Human African trypanosomiasis caused by Trypanosoma brucei gambiense (gambiense HAT) in patients with late-stage disease requires hospital admission to receive nifurtimox-eflornithine combination therapy (NECT). Fexinidazole, the latest treatment that has been recommended by WHO, also requires systematic admission to hospital, which is problematic in areas with few health-care resources. We aim to assess the safety and efficacy of acoziborole in adult and adolescent patients with gambiense HAT.This multicentre, prospective, open-label, single-arm, phase 2/3 study recruited patients aged 15 years or older with confirmed gambiense HAT infection from ten hospitals in the Democratic Republic of the Congo and Guinea. Inclusion criteria included a Karnofsky score greater than 50, ability to swallow tablets, a permanent address or traceability, ability to comply with follow-up visits and study requirements, and agreement to hospital admission during treatment. Oral acoziborole was administered as a single 960 mg dose (3 × 320 mg tablets) to fasted patients. Patients were observed in hospital until day 15 after treatment administration then for 18 months as outpatients with visits at 3, 6, 12, and 18 months. The primary efficacy endpoint was the success rate of acoziborole treatment at 18 months in patients with late-stage gambiense HAT (modified intention-to-treat [mITT] population), based on modified WHO criteria. A complementary post-hoc analysis comparing the 18-month success rates for acoziborole and NECT (using historical data) was performed. This study is registered at ClinicalTrials.gov, NCT03087955.Between Oct 11, 2016, and March 25, 2019, 260 patients were screened, of whom 52 were ineligible and 208 were enrolled (167 with late-stage and 41 with early-stage or intermediate-stage gambiense HAT; primary efficacy analysis set). All 41 (100%) patients with early-stage or intermediate-stage and 160 (96%) of 167 with late-stage disease completed the last 18-month follow-up visit. The mean age of participants was 34·0 years (SD 12·4), including 117 (56%) men and 91 (44%) women. Treatment success rate at 18 months was 95·2% (95% CI 91·2-97·7) reached in 159 of 167 patients with late-stage gambiense HAT (mITT population) and 98·1% (95·1-99·5) reached in 159 of 162 patients (evaluable population). Overall, 155 (75%) of 208 patients had 600 treatment-emergent adverse events. A total of 38 drug-related treatment-emergent adverse events occurred in 29 (14%) patients; all were mild or moderate and most common were pyrexia and asthenia. Four deaths occurred during the study; none were considered treatment related. The post-hoc analysis showed similar results to the estimated historical success rate for NECT of 94%.Given the high efficacy and favourable safety profile, acoziborole holds promise in the efforts to reach the WHO goal of interrupting HAT transmission by 2030.Bill & Melinda Gates Foundation, UK Aid, Federal Ministry of Education and Research, Swiss Agency for Development and Cooperation, Médecins Sans Frontières, Dutch Ministry of Foreign Affairs, Norwegian Agency for Development Cooperation, Norwegian Ministry of Foreign Affairs, the Stavros Niarchos Foundation, Spanish Agency for International Development Cooperation, and the Banco Bilbao Vizcaya Argentaria Foundation.For the French translation of the abstract see Supplementary Materials section." @default.
• W4310644346 created "2022-12-13" @default.
• W4310644346 creator A5001560979 @default.
• W4310644346 creator A5003393056 @default.
• W4310644346 creator A5011647060 @default.
• W4310644346 creator A5015918139 @default.
• W4310644346 creator A5018342398 @default.
• W4310644346 creator A5023103742 @default.
• W4310644346 creator A5023585185 @default.
• W4310644346 creator A5024434540 @default.
• W4310644346 creator A5026297854 @default.
• W4310644346 creator A5028639391 @default.
• W4310644346 creator A5029830398 @default.
• W4310644346 creator A5030878686 @default.
• W4310644346 creator A5032281855 @default.
• W4310644346 creator A5040769435 @default.
• W4310644346 creator A5041516138 @default.
• W4310644346 creator A5043506573 @default.
• W4310644346 creator A5047580490 @default.
• W4310644346 creator A5058037660 @default.
• W4310644346 creator A5065042815 @default.
• W4310644346 creator A5067567011 @default.
• W4310644346 creator A5070053416 @default.
• W4310644346 creator A5070695140 @default.
• W4310644346 creator A5074692795 @default.
• W4310644346 creator A5077931859 @default.
• W4310644346 creator A5079174875 @default.
• W4310644346 creator A5079692423 @default.
• W4310644346 creator A5082857649 @default.
• W4310644346 creator A5084616168 @default.
• W4310644346 creator A5085462102 @default.
• W4310644346 creator A5087156794 @default.
• W4310644346 creator A5090892765 @default.
• W4310644346 date "2023-04-01" @default.
• W4310644346 modified "2023-10-03" @default.
• W4310644346 title "Efficacy and safety of acoziborole in patients with human African trypanosomiasis caused by Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial" @default.
• W4310644346 cites W2007025107 @default.
• W4310644346 cites W2030387285 @default.
• W4310644346 cites W2055475046 @default.
• W4310644346 cites W2077451644 @default.
• W4310644346 cites W2097156911 @default.
• W4310644346 cites W2110499439 @default.
• W4310644346 cites W2149958970 @default.
• W4310644346 cites W2151799620 @default.
• W4310644346 cites W2275119563 @default.
• W4310644346 cites W2276434364 @default.
• W4310644346 cites W2765696050 @default.
• W4310644346 cites W2914404546 @default.
• W4310644346 cites W3000524669 @default.
• W4310644346 cites W3214482058 @default.
• W4310644346 cites W4205265340 @default.
• W4310644346 cites W4210387299 @default.
• W4310644346 cites W4309889315 @default.
• W4310644346 doi "https://doi.org/10.1016/s1473-3099(22)00660-0" @default.
• W4310644346 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36460027" @default.
• W4310644346 hasPublicationYear "2023" @default.
• W4310644346 type Work @default.
• W4310644346 citedByCount "13" @default.
• W4310644346 countsByYear W43106443462023 @default.
• W4310644346 crossrefType "journal-article" @default.
• W4310644346 hasAuthorship W4310644346A5001560979 @default.
• W4310644346 hasAuthorship W4310644346A5003393056 @default.
• W4310644346 hasAuthorship W4310644346A5011647060 @default.
• W4310644346 hasAuthorship W4310644346A5015918139 @default.
• W4310644346 hasAuthorship W4310644346A5018342398 @default.
• W4310644346 hasAuthorship W4310644346A5023103742 @default.
• W4310644346 hasAuthorship W4310644346A5023585185 @default.
• W4310644346 hasAuthorship W4310644346A5024434540 @default.
• W4310644346 hasAuthorship W4310644346A5026297854 @default.
• W4310644346 hasAuthorship W4310644346A5028639391 @default.
• W4310644346 hasAuthorship W4310644346A5029830398 @default.
• W4310644346 hasAuthorship W4310644346A5030878686 @default.
• W4310644346 hasAuthorship W4310644346A5032281855 @default.
• W4310644346 hasAuthorship W4310644346A5040769435 @default.
• W4310644346 hasAuthorship W4310644346A5041516138 @default.
• W4310644346 hasAuthorship W4310644346A5043506573 @default.
• W4310644346 hasAuthorship W4310644346A5047580490 @default.
• W4310644346 hasAuthorship W4310644346A5058037660 @default.
• W4310644346 hasAuthorship W4310644346A5065042815 @default.
• W4310644346 hasAuthorship W4310644346A5067567011 @default.
• W4310644346 hasAuthorship W4310644346A5070053416 @default.
• W4310644346 hasAuthorship W4310644346A5070695140 @default.
• W4310644346 hasAuthorship W4310644346A5074692795 @default.
• W4310644346 hasAuthorship W4310644346A5077931859 @default.
• W4310644346 hasAuthorship W4310644346A5079174875 @default.
• W4310644346 hasAuthorship W4310644346A5079692423 @default.
• W4310644346 hasAuthorship W4310644346A5082857649 @default.
• W4310644346 hasAuthorship W4310644346A5084616168 @default.
• W4310644346 hasAuthorship W4310644346A5085462102 @default.
• W4310644346 hasAuthorship W4310644346A5087156794 @default.
• W4310644346 hasAuthorship W4310644346A5090892765 @default.
• W4310644346 hasBestOaLocation W43106443461 @default.
• W4310644346 hasConcept C126322002 @default.
• W4310644346 hasConcept C141071460 @default.
• W4310644346 hasConcept C187212893 @default.
• W4310644346 hasConcept C197934379 @default.
• W4310644346 hasConcept C203014093 @default.
• W4310644346 hasConcept C203092338 @default.

• next